ArticleAdvanced pharmaceutical bulletin2025
Mebendazole-Treated Human Monocyte-Derived Dendritic Cells Represent Promoted Immunogenic Phenotype with Augmented Expression of Inflammatory Markers.
Article in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Voriconazole treated human monocyte derived dendritic cells exhibit modulatory features with augmented surface expression of maturation and stimulatory markers.Molecular biology reports · 2026Article
- Paclitaxel and B7-H6 knockdown inhibit HepG2 hepatocellular carcinoma cell viability and migration, while enhancing apoptosis and cell cycle arrest.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Dendritic cells (DCs) play a critical role in regulating immune responses by influencing the balance between immune tolerance and immunogenicity. While mebendazole (MBZ) is known to polarize macrophages toward a tumor-suppressive phenotype, its effect on DCs remains unclear. This study investigates the effects of MBZ on the phenotype and inflammatory profile of human monocyte-derived dendritic cells (moDCs). Methods: Peripheral blood mononuclear cells (PBMCs) were separated from the obtained blood from healthy donors using Ficoll density gradient centrifugation. Then, monocytes were isolated via plastic adhesion and subsequently differentiated into moDCs. Cells were treated with MBZ and lipopolysaccharide (LPS) or just LPS, and then surface markers and inflammatory/anti-inflammatory gene expression were measured using flow cytometry and real-time PCR. Results: The study compared surface marker expression and gene expression of inflammatory and anti-inflammatory cytokines between moDCs and MBZ-moDCs. MBZ-moDCs showed significantly higher CD86 surface expression but lower CD11c and HLA-DR expression in comparison to moDCs. Additionally, MBZ-moDCs exhibited increased interleukin (IL)-12, IL-18, IL-1β, and TNF-α gene levels and decreased IL-10 and IDO levels. Conclusion: MBZ holds significant potential for reshaping immunotherapy by exerting a profound impact on dendritic cells. By comprehending the intricate interaction between MBZ and dendritic cell function, innovative interventions can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.